指南与共识胸部肿瘤

医疗补助扩展与非小细胞肺癌分期、及时规范治疗及生存的关联

Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non-Small Cell Lung Cancer.
指南 / 共识 · J Clin Oncol · 2026-02-13

该研究基于美国国家癌症数据库,纳入2004至2023年确诊的I–IV期非小细胞肺癌(NSCLC)患者,采用双重差分(DID)方法比较医疗补助扩展州与非扩展州。结果显示,扩展州早期诊断率提高1.02个百分点,30天内及时启动指南一致治疗提高2.10个百分点,5年总生存(OS)提高1.79个百分点,提示医疗补助扩展改善了NSCLC的早期发现、治疗及时性与生存。

要点

  • 医疗补助扩展与NSCLC早期诊断率提高1.02个百分点相关
  • 扩展州30天内及时启动指南一致治疗提高2.10个百分点
  • 扩展州5年OS提高1.79个百分点,低收入地区人群获益更明显

核心结论

  • 医疗补助扩展与NSCLC早期诊断、指南一致治疗的及时性及5年OS改善相关,预期中的医疗补助覆盖损失可能危及这些获益。

研究设计与样本

  • 扩展州350,290例,非扩展州164,228例;采用传统与更新(Sun和Abraham)双重差分(DID)方法,分期与治疗用多变量线性概率模型,生存用多变量灵活参数生存模型。

主要发现

  • 与非扩展州相比,扩展州人群更多为女性、非西班牙裔白人,或居住于家庭收入较高地区或非都市地区。
  • 医疗补助扩展与早期NSCLC诊断增加相关(DID:1.02个百分点[95%CI,0.52至1.52])。
  • 医疗补助扩展与及时启动治疗增加相关(DID:2.10个百分点[95%CI,0.05至4.15])。
  • 医疗补助扩展与5年OS提高相关(DID:1.79个百分点[95%CI,1.32至2.26])。
  • 分层分析显示,居住于较低家庭收入地区的人群更可能从医疗补助扩展中获益。

临床怎么用

  • 对NSCLC患者应关注医保覆盖状态,医疗补助扩展可能促进早期诊断、及时启动指南一致治疗并改善生存。
  • 在低收入地区人群中,应重视医保政策对肺癌诊疗可及性与生存获益的影响。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the associations between Medicaid expansion and stage at diagnosis, timely initiation and receipt of guideline-concordant treatment, and 5-year overall survival (OS) among people with non-small cell lung cancer (NSCLC). METHODS: Individuals newly diagnosed with stage I to IV NSCLC at age 18-64 years between January 1, 2004, and December 31, 2023, in 50 states and Washington, DC, were identified from the National Cancer Database. We examined the association of Medicaid expansion and (1) early-stage diagnosis (I and II); (2) timely initiation of guideline-concordant treatment within 30 days after diagnosis; (3) receipt of all first-course guideline-concordant treatment; and (4) 5-year OS. We applied conventional and updated (Sun and Abraham) difference-in-differences (DID) approaches to examine the changes in study outcomes associated with Medicaid expansion using multivariable linear probability models to estimate stage and treatment and multivariable flexible parametric survival models to investigate survival overall and by key factors. RESULTS: Compared with people in nonexpansion states (n = 164,228), people in expansion states (n = 350,290) were more likely to be female, non-Hispanic White, or living in areas with higher family income or in nonmetropolitan areas. Medicaid expansion was associated with increases in early-stage NSCLC diagnosis (DID: 1.02 percentage points [ppt; 95% CI, 0.52 to 1.52]), timely treatment initiation (2.10 ppt [95% CI, 0.05 to 4.15]), and higher 5-year OS (1.79 ppt [95% CI, 1.32 to 2.26]). In stratified analyses, people living in areas with lower household income were more likely to benefit from Medicaid expansion. CONCLUSION: Medicaid expansion was associated with improvements in early detection, timeliness of guideline-concordant treatment, and survival for people with NSCLC. Anticipated Medicaid coverage losses may jeopardize these gains.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao J, Graetz I, Howard D, et al. Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non-Small Cell Lung Cancer. J Clin Oncol. 2026. PMID: 41687045. doi:10.1200/JCO-25-01892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。